A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
|Articles|January 20, 2005
Dr. Tewari to head Cornell Institute of Robotic Urological Surgery
Ashutosh Tewari, MD, has been named director of robotic prostatectomy and prostate cancer outcomes in the Brady Urologic Health Center of the department of urology and the department of public health at New York-Presbyterian/Weill Cornell Medical Center.
Advertisement
Advertisement
Related to this article
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
The AACU and the WOCN Society urge CMS to protect access to individualized catheter and ostomy supplies as competitive bidding begins in 2028.
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves belzutifan plus lenvatinib for advanced clear cell renal cell carcinoma
2
FDA grants priority review to perioperative durvalumab plus enfortumab vedotin in MIBC
3
After curative-intent treatment, prostate cancer recurrence is still an unmet need
4
Sandip Prasad, MD, on patient selection for chemoablation in LG-IR-NMIBC
5